Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia

Journal of Microbiology, Immunology and Infection

Volumn 45, Issue 3, 2012, Pages 214-220

  Yeh, Yen Cheng ^a,b   Yeh, Kuo Ming ^b   Lin, Te Yu ^b   Chiu, Sheng Kang ^b   Yang, Ya Sung ^b   Wang, Yung Chih ^b   Lin, Jung Chung ^b  

^a KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Bacteremia; Etest; Methicillin resistant Staphylococcus aureus; Minimum inhibitory concentration; Vancomycin creep

Indexed keywords

VANCOMYCIN;

AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; BACTEREMIA; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TAIWAN; VANCOMYCIN;

EID: 84861226487     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2011.11.006     Document Type: Article

References (23)

1. Tseng S.H., Lee C.M., Lin T.Y., Chang S.C., Chang F.Y. Emergence and spread of multi-drug resistant organisms: think globally and act locally. J Microbiol Immunol Infect 2011, 44:157-165.
2. Lode H.M. Clinical impact of antibiotic-resistant Gram-positive pathogens. Clin Microbiol Infect 2009, 15:212-217.
3. Appelbaum P.C. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2007, 30:398-408.
4. Maor Y., Hagin M., Belausov N., Keller N., Ben-David D., Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009, 199:619-624.
5. Soriano A., Marco F., Martínez J.A., Pisos E., Almela M., Dimova V.P., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46:193-200.
6. Howden B.P., Ward P.B., Charles P.G., Korman T.M., Fuller A., du Cros P., et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004, 38:521-528.
7. Wang J.L., Wang J.T., Sheng W.H., Chen Y.C., Chang S.C. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/μL, by the broth microdilution method. BMC Infect Dis 2010, 10:159-165.
8. Lodise T.P., Graves J., Evans A., Graffunder E., Helmecke M., Lomaestro B.M., et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008, 52:3315-3320.
9. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering R.C., Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004, 42:2398-2402.
10. Steinkraus G., White R., Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007, 60:788-794.
11. Wang G., Hindler J.F., Ward K.W., Bruckner D.A. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006, 44:3883-3886.
12. Ho P.L., Lo P.Y., Chow K.H., Lau E.H., Lai E.L., Cheng V.C., et al. Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J Infec 2010, 60:140-145.
13. Alós J.I., García-Cañas A., García-Hierro P., Rodríguez-Salvanés F. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J Antimicrob Chemother 2008, 62:773-775.
14. Kehrmann J., Kaase M., Szabados F., Gatermann S.G., Buer J., Rath P.M., et al. Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem?. Eur J Clin Microbiol Infect Dis 2011, 30:677-683.
15. World Health Organization Collaborating Centre for Drug Statistics Methodology. Available from: [accessed 15.11.10]. http://www.whocc.no/atc_ddd_index/.
16. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, M7eA6 2006, Clinical and Laboratory Standard Institute, Clinical and Laboratory Standard Institute, Wayne, Pa.
17. Liu C., Bayer A., Cosgrove S.E., Daum R.S., Fridkin S.K., Gorwitz R.J., et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011, 52:285-292.
18. Rybak M.J., Lomaestro B.M., Rotschafer J.C., Moellering R.C., Craig W.A., Billeter M., et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009, 49:325-327.
19. Robert J., Bismuth R., Jarlier V. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J Antimicrob Chemother 2006, 57:506-510.
20. Jones R.N. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006, 42(Suppl. 1):S13-S24.
21. Musta A.C., Riederer K., Shemes S., Chase P., Jose J., Johnson L.B., et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009, 47:1640-1644.
22. Lodise T.P., Miller C.D., Graves J., Evans A., Graffunder E., Helmecke M., et al. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008, 62:1138-1141.
23. Paiva R.M., Mombach Pinheiro Machado A.B., Zavascki A.P., Barth A.L. Vancomycin MIC for methicillin-resistant coagulase-negative Staphylococcus isolates: evaluation of the broth microdilution and Etest methods. J Clin Microbiol 2010, 48:4652-4654.